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Background: Atopic dermatitis (AD) is a common, complex 
disease that follows a chronic relapsing course and sig-
nificantly affects the quality of life of patients. Skin barrier 
dysfunction and inflammatory processes induce and ag-
gravate this skin condition. Proper use of an emollient for hy-
dration is a keystone of AD treatment. Bee venom is known 
to have anti-inflammatory effects and has been widely used 
in traditional medicine to treat various inflammatory 
disorders. Objective: To find out the beneficial effect of an 
emollient containing bee venom in the treatment of patients 
with AD. Methods: This study included 136 patients with AD 
who were randomized to receive either an emollient con-
taining bee venom and silk-protein or a vehicle that was iden-
tical except for the bee venom for 4 weeks. The patients were 
instructed to apply the emollient twice daily on their entire 
body and not to use other medications, including topicals, 
during the course of the study. The eczema area and severity 
index (EASI) score, transepidermal water loss, and visual ana-
logue scale (VAS) score of itching were evaluated at the first 
visit and after 2 and 4 weeks. The investigator global assess-
ment was evaluated at 2 and 4 weeks after the application of 
emollient containing bee venom or vehicle. Results: Patients 
applying emollient containing bee venom showed sig-
nificantly lower EASI score and VAS value compared to pa-
tients applying emollient without bee venom. Conclusion: 
Emollient containing bee venom is a safe and effective option 
for patients with AD. (Ann Dermatol 28(5) 593∼599, 2016)
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INTRODUCTION
Atopic dermatitis (AD) is a chronic, relapsing skin disorder 
characterized by defects in epidermal barrier function and 
cutaneous inflammation1. It is one of the most common 
skin diseases, estimated to be present in up to 20% of chil-
dren and 1%∼3% of adults worldwide2. Although the 
pathophysiology of AD remains unclear, epidermal barrier 
dysfunction due to genetic defects and immunologic re-
sponses plays a key role in the development and ag-
gravation of AD1. Whether epidermal dysfunction pre-
cedes immune dysregulation (‘outside-in’ hypothesis) or 
immune dysregulation precedes barrier abnormalities (‘in-
side-out’ hypothesis), it is clear that skin barrier function is 
important in the pathophysiology of AD3. The ‘brick and 
cement’ structure of skin keratinocytes functions as a bar-
rier, protecting skin from exogenous material and prevent-
ing moisture loss. Barrier disruption due to abnormal lipid 
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metabolism and abnormal structural protein formation 
(filaggrin, etc.) facilitates allergen penetration into the skin, 
increasing the risk of subsequent inflammation and con-
tributing to chronic and recalcitrant eczema2. While acute 
flares should be managed with topical steroids and im-
munomodulators, the fundamental therapy for AD is 
based on skin hydration and restoration of the disrupted 
skin barrier. As skin xerosis and barrier dysfunction are the 
main symptoms of AD, regular use of appropriate emol-
lients remains the mainstay of maintenance therapy2. Skin 
hydration and replacement of membrane lipids improve 
xerosis, maintains skin barrier function, relieves pruritus, 
and have a steroid-sparing effect2,4. 
In the acute phase of AD, inflammatory dendritic epi-
dermal cells, differentiated from recruited monocytes, pro-
duce the proinflammatory cytokines interleukin (IL)-1, 
IL-6, and tumor necrosis factor (TNF)-α5. Type 2 helper T 
(Th2) inflammatory responses occur predominantly in the 
initiation stage of AD2. Th2 cytokines, such as IL-4, IL-13, 
IL-17, are also increased in acute skin lesions. The cyto-
kines produced during the initial stage of disease develop-
ment increase the expression of chemokines and adhesion 
molecules, which leads to the recruitment of leukocytes in 
the skin6. In contrast, Th1 cell-mediated responses occur 
in the chronic phase, with increases in interferon-γ. Thus, 
application of topical and systemic anti-inflammatory 
agents is important in the management of AD, resulting in 
the prevention of these pathogenic reactions.
Patients with AD have a predisposition to colonization and 
infection by a number of microbial organisms, especially 
Staphylococcus aureus3. Moreover, a number of reports 
have revealed a positive correlation between S. aureus col-
onization density and AD severity3,7. S. aureus-derived 
products, such as toxins with superantigenic properties 
and lipoteichoic acid, can exacerbate disease. The severity 
of AD can be improved with antistaphylococcal antibiotic 
treatment8. Moreover, the prevention of colonization by S. 
aureus in normal skin may prevent secondary eczematous 
lesions caused by subsequent inflammatory responses. 
Thus, one of the important goals of AD treatment should 
be the eradication of S. aureus residing in patient skin.
Bee venom has been used in traditional medicine to treat 
various inflammatory conditions. Some studies have dem-
onstrated the anti-inflammatory effects of bee venom, re-
porting downregulation of IL-1 and TNF-α through sup-
pression of nuclear factor (NF)-κB5,9. Moreover, several 
reports have demonstrated that melittin, the main compo-
nent of bee venom, has antimicrobial activity, especially 
against S. aureus10,11. Based on these previous studies, 
emollient containing bee venom is expected to have a 
beneficial effect in treating AD, due to its anti-in-
flammatory as well as anti-microbial properties. Therefore, 
in the present clinical trial, we aimed to investigate the 
beneficial effects of an emollient containing bee venom 
and silk protein, which is known as an emollient for its 
hydrating potency, with regard to improvement in disease 
severity, skin barrier function, and pruritus relief. 
MATERIALS AND METHODS
Methods
This study included 136 patients with AD randomized to 
receive an emollient containing bee venom and silk-protein 
(Dongsung Pharmaceutical, Seoul, Korea) (experimental 
group) or a vehicle (vehicle group) that was identical to 
the test compound except for the bee venom for 4 weeks. 
Subjects in both the experimental and vehicle groups 
were instructed to apply the cream twice daily on the en-
tire body and not to use other medications, including top-
ical medication, during the course of the study. The pa-
tients were evaluated at baseline, 2, and 4 weeks by a pri-
mary investigator. The primary endpoint of the study was 
the eczema area and severity index (EASI) score in both 
groups. The secondary endpoints were transepidermal wa-
ter loss (TEWL), pruritus relief, and investigator global as-
sessment (IGA) score. The EASI score was calculated for 
the affected area and eczema severity by a primary 
investigator. TEWL was measured using a TewameterⓇ 
TM 210 (Courage-Khazaha, Koln, Germany) on same spot 
of the right forearm of the patient regardless of the pres-
ence of eczema lesion, according to the manufacturer’s 
guidelines. Pruritus relief was assessed with a visual ana-
logue scale (VAS) by the patients themselves. This scale 
assigns a numeric value to pruritus severity from 1 to 10, 
with 10 being most severe. IGA was graded on a sev-
en-point scale (1, greatly worsened; 2, moderately wors-
ened; 3, worsened slightly; 4, no change; 5, slightly im-
proved; 6, moderately improved; 7, greatly improved) by 
a primary investigator during visits 2 and 3. Adverse drug 
reactions were evaluated in all patients during visits 2 and 
3. The severity of adverse drug reactions was classified as 
mild (does not impair daily activity and does not require 
treatment), moderate (impairs daily activity and requires 
treatment), severe (severely impairs daily activity and may 
require admission), and life threatening. 
For appropriate statistical analysis, we calculated the re-
quired number of patients. To achieve a statistical power 
of 1–β ≥0.8 at a significance level of 0.05, it is known 
that (1+λ)σ2(zα/2+z1-β)2/λ(μa−μb) ≤n is required 
(μa=the average value of the EASI score in the ex-
perimental group, μb=the average value of the EASI 
score in the vehicle group, λ=the required number of 
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Table 1. Demographic characteristics and baseline data of the experimental and vehicle groups (n=114)
Characteristic Experimental group (n=55) Vehicle group (n=59) p-value
Age (yr) 18.31±13.51 (2, 50) 14.63±10.46 (2, 53) 0.109
Sex 0.851
  Male 28 (50.9) 28 (47.5)
  Female 27 (49.1) 31 (52.5)
EASI score  9.29±3.71 (5, 19)     9.78±4.97 (3.1, 28.4) 0.546
TEWL (right forearm) 27.87±13.5 (9, 65) 26.54±13.92 (8.7, 68) 0.606
VAS for pruritus 5.53±1.82 (2, 9) 5.08±1.97 (1, 9) 0.215
Values are presented as mean±standard deviation (min, max) or number (%). EASI: eczema area severity index, TEWL: transepidermal
water loss, VAS: visual analogue scale.
patients in the vehicle group, n=the required number of 
patients in the experimental group). It is known that λ=1 
is needed for minimization of the number of patients. In a 
previous study12, the average EASI score was 9.51 at 
baseline. From the results of another study on the use of 
emollient13, the EASI score of the vehicle group was ex-
pected to decrease by 37.5% after 4 weeks. Moreover, 
from the results of a previous study comparing an emol-
lient containing bee venom and vehicle in NC/Nga mice, 
the EASI score decrease in the experimental group was ex-
pected to be 1.44 times higher than that in the vehicle 
group. Based on these results, μa−μb was estimated to 
be 1.57. From the results of a previous clinical study13, 
Var(Xb)=2.51 and Var(Xa)=5.12 (Xb=EASI score at the 
baseline, Xa=EASI score after 4 weeks) were assumed, 
and σ2 was estimated to be 7.63. Finally, the required 
number of patients for appropriate statistical analysis was 
at least 49 for each the experimental group and vehicle 
group. Considering a 20% drop-out rate, the required 
number of patients for each group was estimated to be 62. 
Based on this, we decided to enroll at least 124 patients in 
this study.
Patients
For this study, 136 patients with AD who visited Severance 
Hospital, Seoul National University Hospital, Hallym 
University Kangnam Sacred Heart Hospital, Chung-Ang 
University Hospital, or Incheon St. Mary’s Hospital were 
enrolled between the beginning of September 2014 and 
the end of January 2015. This study was approved by the 
Incheon St. Mary’s Hospital Institutional Review Board 
(IRB no. OC14MIMI0080). The diagnosis of AD was based 
on the modified Hanifin and Rajka’s criteria. The inclusion 
criteria were defined as follows: (1) Age 2 years or older; 
(2) EASI score 5 or higher; (3) Patients who voluntarily 
agreed to participate in the study (in case of patient under 
age 18, a legal guardian agreed to participate in the study). 
The exclusion criteria were defined as follows: (1) 
Treatment with any systemic immunosuppressive agents 
or immunomodulators within 1 month of the study; (2) 
treatment with any anti-histaminergic agents within 1 
week of the study; (3) previous hypersensitivity reaction to 
bee venom in the 5 years before the study. Patients who 
applied topical medications, including topical cortico-
steroids, were included in the study, but they were not al-
lowed to apply them during the course of the study. 
Statistical analysis
Statistical analysis was performed using SAS ver. 9.3 
(Statistical Analysis System, Cary, NC, USA). T-test was 
used for continuous data and a Wilcoxon rank sum test for 
categorical data. The principle of last observation carried 
forward was used in both analyses, using the score re-
corded just prior to the missing scores in cases of missing 
post-treatment values. The data were analyzed for the 
group adhering to the study with an “intention-to-treat” ap-
plication model (full analysis set, FAS) for analysis of data 
for clinical trials. Test results that produced p-values 
＜0.05 were regarded as statistically significant.
RESULTS
Of the 136 patients who were initially enrolled, 22 who 
violated FAS criteria were excluded from the statistical 
analysis for not visiting the hospital at least once after ap-
plication of the emollient. The remaining 114 individuals 
who were evaluated at least once in addition to the base-
line evaluation were included in statistical analysis. No 
statistically significant differences were present in number 
of early withdrawals between the experimental and ve-
hicle groups. No statistically significant differences were 
noted at baseline between the two groups based on age, 
sex, TEWL, EASI score, or VAS score for pruritus (Table 1). 
EASI score
The decreases in EASI scores during the study period are 
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Fig. 1. Comparison of the outcomes at visit 2 and visit 3, assessed as change from baseline: (A) The percent decrease in eczema 
area severity index (EASI) score. (B) The percent decrease in transepidermal water loss (TEWL). (C) Decrease in visual analogue scale 
(VAS) score for pruritus. *Statistically significant decrease compared to vehicle group.
Table 2. Efficacy assessment at visit 2 and visit 3
Visit Experimental group Vehicle group p-value
Decrease in EASI score (%) Visit 2 −25.16±3.91
(−32.91 to −17.40)
−13.47±3.27
(−19.95 to −7.00)
0.023*
Visit 3 −34.69±4.55
(−43.70 to −25.67)
−19.66±4.64
(−28.87 to −10.46)
0.022*
Decrease in TEWL (%) Visit 2 6.15±8.65
(−11.00 to 23.30)
14.48±6.02
 (2.56 to 26.41)
0.427
Visit 3 6.97±7.25
(−7.41 to 21.35)
12.98±7.78
(−2.45 to 28.41)
0.571
Decrease in VAS for pruritus Visit 2 −0.95±0.25
(−1.45 to −0.45)
−0.48±0.24
(−0.96 to −0.01)
0.179
Visit 3 −1.50±0.31
(−2.12 to −0.88)
−0.55±0.30
(−1.14 to 0.04)
0.030*
Values are presented as mean±standard deviation (95% confidence interval). EASI: eczema area severity index, TEWL: transepidermal
water loss, VAS: visual analogue scale. *Statistically significant difference compared to the vehicle group.
shown in Table 2 and Fig. 1A. The EASI score of the ex-
perimental group was significantly decreased from 9.29± 
3.71 at baseline. The percent decrease of EASI score was 
−25.16%±3.91% (p=0.023) at visit 2 and −34.69%± 
4.55% (p=0.022) at visit 3, which were significantly larger 
compared to the values for the vehicle group (−13.47%± 
3.27% at visit 2 and −19.66%±4.64% at visit 3).
Transepidermal water loss
The changes in TEWL value are shown in Table 2 and Fig. 
1B. From 27.87±13.5 at baseline, the TEWL value meas-
ured on the right forearm of the experimental group 
changed by 6.15%±8.65% (p=0.427) and 6.97%±7.25% 
(p=0.571) when measured during visit 2 and visit 3, 
respectively. The decreases in TEWL value were not statisti-
cally significantly different between the experimental group 
and the vehicle group. 
VAS score for pruritus
The changes in VAS score for pruritus are shown in Table 2 
and Fig. 1C. The VAS score for pruritus was significantly de-
creased in the experimental group at visit 3. From 5.53± 
1.82 at baseline, decreases of −0.95±0.25 (p=0.179) at 
visit 2 and −1.50±0.31 (p=0.03) at visit 3 were observed, 
compared to the vehicle group, which showed −0.48± 
0.24 and −0.55±0.30 decreases at visit 2 and visit 3, 
respectively.
Investigator global assessment
The results of the IGA are shown in Fig. 2. A Wilcoxon 
rank sum test was used to identify the differences between 
the treated and untreated groups. No statistically sig-
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Table 3. Adverse drug reactions
Total Experimental group Vehicle group p-value*
Aggravation of dermatitis 10 (7.4) 5 (7.0) 5 (7.7) ＞0.999
Irritation 5 (3.7) 4 (5.6) 1 (1.5) 0.368
Pruritus 13 (9.6) 8 (11.3) 5 (7.7) 0.567
Erythema 4 (2.9) 3 (4.2) 1 (1.5) 0.621
Urticaria 3 (2.2) 2 (2.8) 1 (1.5) ＞0.999
Local edema 1 (0.7) 1 (1.4) 0 ＞0.999
Conjunctivitis 1 (0.7) 1 (1.4) 0 ＞0.999
Acute bronchiolitis 1 (0.7) 0 1 (1.5) 0.478
Common cold 3 (2.2) 3 (4.2) 0 0.246
Upper respiratory infection 1 (0.7) 1 (1.4) 0 ＞0.999
Itching sensation 4 (2.9) 1 (1.4) 3 (4.6) 0.348
Other erythematous condition 3 (2.2) 1 (1.4) 2 (3.1) 0.606
Scabies 1 (0.7) 1 (1.4) 0 ＞0.999
Other rash 2 (1.5) 2 (2.8) 0 0.497
Nasopharyngitis 1 (0.7) 0 1 (1.5) 0.478
Xerosis 1 (0.7) 1 (1.4) 0 ＞0.999
Values are presented as number (%). *Statistically significant difference compared to the vehicle group.
Fig. 2. Investigator global assessment (IGA) at (A) visit 2 (2 weeks); (B) visit 3 (4 weeks).
nificant difference was noted between the experimental 
and vehicle groups at visit 2 (p=0.1086) or visit 3 
(p=0.4228).
Adverse drug reactions
All of the reported adverse drug reactions are shown in 
Table 3. Irritation (5), pruritus (13), erythema (4), urticaria 
(3), and disease exacerbation (10) were commonly re-
ported as adverse cutaneous drug reactions. All of the re-
ported adverse reactions were classified as mild, which 
did not impair daily activity and did not require any 
treatment. Of the 71 patients who applied emollient con-
taining bee venom, 25 (35.2%) experienced adverse drug 
reactions. Of the 65 patients who applied the vehicle, 15 
(23.1%) experienced adverse drug reactions. There were 
no statistically significant differences in the incidence of 
adverse drug reactions between the experimental and ve-
hicle groups (p=0.135, Fisher’s exact test). Incidences of 
all reported adverse drug reactions showed no statistically 
significant difference between two groups. 
DISCUSSION 
In the present study, we demonstrated the efficacy and 
safety of emollient containing bee venom for the treatment 
of AD. To our knowledge, this is the first clinical study 
demonstrating the efficacy of bee venom on human skin. 
The experimental group showed a significant improve-
ment in EASI score and VAS score for pruritus. However, 
the TEWL and IGA values did not differ from those in the 
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vehicle group. This may be due to the hydrating effect of 
silk protein. Silk protein is an ingredient registered in the 
international cosmetic ingredient dictionary and is widely 
used in cosmetics for its excellent moisture-binding 
properties. In this study, silk protein was used as a vehicle 
and applied identically in both the experimental group 
and the vehicle group. The moisturizing effect of silk pro-
tein might have improved the skin barrier function and, 
therefore, lessened the differences in TEWL and IGA be-
tween the two groups of patients.
The rationale for barrier repair therapy in AD goes beyond 
trapping moisture and preventing xerosis14. Restoration of 
the normal skin barrier function by emollient use can 
down-regulate inflammation and reduce the symptoms 
and flares of AD15. Additionally, regular use of emollient 
may also reduce the need for topical corticosteroid by 
50%16. Consequently, regular use of emollient is im-
portant in AD management.
From an immunologic point of view, in the acute phase of 
AD, recruited monocytes produce proinflammatory cyto-
kines, such as TNF-α and IL-1β, which are important in 
regulating T cell activation and in stimulating the acute 
phase reaction, supporting the recruitment, proliferation, 
and survival of leukocytes in the skin6. There have been 
reports suggesting that TNF-α and IL-1β play important 
roles in eczema development with increasing skin irrita-
bility and pruritus5,17.
Among the colonized microbial organisms in AD patient’s 
skin, S. aureus is cultured from 90% of eczematous le-
sions and also resides in normal-appearing skin in AD pa-
tients18. Colonization by S. aureus not only increases the 
risk of infection, but also exacerbates skin inflammation 
through secretion of toxins with superantigenic properties, 
resulting in activation of T cells and other immune system 
components. Staphylococcal superantigens induce mast 
cell degranulation and specific IgE antibody production 
that leads to T cell proliferation and increases in IL-31, 
which induces pruritus. Thus, S. aureus contribute to pru-
ritus and to the inflammatory changes in AD skin3,15.
Recently, much attention has been focused on discovering 
substances used in traditional medicine and evaluating 
their efficacy and safety. Bee venom has been used in 
China, Japan, and Korea for the treatment of various in-
flammatory disorders, including arthritis. Bee venom is a 
complex mixture of at least 18 pharmacologically active 
components, including melittin, apamin, adolapin, phos-
pholipase A2, and mast cell deregulating peptide11. 
Among these compounds, melittin is the principal toxin 
and the major active peptide, contributing 52% of the dry 
weight of bee venom19. Bee venom, especially the melittin 
component, has been widely researched and has been 
shown to exert various effects. Han et al.20 reported an an-
ti-inflammatory effect of bee venom in rats. In another 
study, it was shown that pre-treatment with bee venom 
significantly inhibited compound 48/80-induced scratch-
ing in rats. Bee venom was shown to have an anti-in-
flammatory effect and suppressed AD-related pruritus by 
reducing degranulation of mast cells and expression of 
pro-inflammatory cytokines. Bee venom or melittin has 
been suggested to inhibit the DNA binding activity of NF-
κB through inhibition of IκB phosphorylation and p50 
translocation. It is possible that bee venom binds directly 
to p50 and inhibits NF-κB activation9. Moreover, several 
studies have clearly demonstrated the broad antibiotic ef-
fects of bee venom, especially with respect to anti-staph-
ylococcal potency11,21. 
Considering the anti-inflammatory effects of bee venom 
and the characteristics of AD, an emollient containing bee 
venom was expected to have advantages over other emol-
lients in treating AD. Our study showed the beneficial ef-
fect of an emollient containing bee venom on AD, result-
ing in significant decreases in EASI score and pruritus. Bee 
venom not only prevented proinflammatory cytokine pro-
duction, but also reduced pruritus and prevented keratino-
cyte damage from scratching, which may reduce the in-
flammatory cytokines released from keratinocytes. These 
anti-inflammatory and pruritus-reducing properties of bee 
venom are effective as maintenance therapy for AD. 
Furthermore, the antibiotic effect of bee venom may im-
prove skin eczema and pruritus by eradicating S. aureus. 
With respect to safety, one study previously showed that 
bee venom applied topically to the skin does not induce 
any irritation or toxicity in rabbits22. Another study 
showed that topically applied bee venom does not induce 
any cutaneous sensitization or anayphlactic reaction in 
mice23. Our study found no significant differences in the 
incidences of adverse reactions caused by bee venom on 
human skin and demonstrated its safety. 
In conclusion, this double-blinded, randomized, con-
trolled, multicenter study suggests that an emollient con-
taining bee venom may be an efficient and safe option for 
patients with AD, resulting in improvements in disease se-
verity and pruritus. 
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